Deciphering Cathepsin K inhibitors: a combined QSAR, docking and MD simulation based machine learning approaches for

S Ilyas1, J Lee1, Y Hwang1

  • 1Department of Herbal Pharmacology, College of Korean Medicine, Gachon University, Seongnam-si, Korea.

Insights

Researchers developed new CatK inhibitors using quantitative structure-activity relationships (QSAR) and machine learning. This approach overcomes severe side effects associated with current CatK inhibitors, paving the way for safer treatments.

Area of Science:

  • Medicinal Chemistry
  • Computational Biology
  • Pharmacology

Background:

  • Cathepsin K (CatK) is implicated in various diseases, including skeletal abnormalities and inflammation.
  • Existing CatK inhibitors have severe adverse effects, limiting their clinical application.

Purpose of the Study:

  • To explore quantitative structure-activity relationships (QSAR) for CatK inhibitors.
  • To develop novel, safer CatK inhibitors using computational methods.

Main Methods:

  • Compiled and analyzed a dataset of 1568 CatK inhibitors from the ChEMBL database.
  • Employed PubChem fingerprinting and 11 machine learning classification models, including the ET model.
  • Utilized molecular docking and molecular dynamics (MD) simulations for structural insights.

Main Results:

  • The ET model demonstrated high accuracy (0.977 on test set), meeting OECD guidelines.
  • Identified CatK inhibitors with strong binding energies (-8.3 and -7.2 kcal/mol).
  • MD simulations confirmed structural stability and interactions of inhibitor-target complexes.

Conclusions:

  • The combination of QSAR, machine learning, docking, and MD simulations provides a robust framework.
  • This integrated approach supports the development of novel and resilient CatK inhibitors with improved safety profiles.

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
668
Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.8K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K